期刊
NEUROCHEMICAL RESEARCH
卷 28, 期 7, 页码 1035-1040出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1023/A:1023207222944
关键词
Parkinson's disease; antiparkinsonian drugs; neuroprotection; bromocriptine; pramipexole; talipexole
Numerous studies have shown that endogenous and/or environmental neurotoxins and oxidative stress may participate in the pathogenesis of Parkinson's disease (PD), but the detailed mechanisms are still unclear. While dopamine (DA) replacement therapy with L-DOPA (levodopa) improves PD symptoms, it does not inhibit the degeneration of DA neurons in the substantia nigra. Recently, bromocriptine, pramipexole and several other agonists of the dopamine D-2-receptor subfamily (including D-2, D-3 and D-4-subtypes) have been shown to have neuroprotective effects in parkinsonian models in vitro and in vivo. Their neuroprotective effects may be mediated directly and/or indirectly by antioxidant effects, mitochondrial stabilization or induction of the antiapoptotic Bcl-2 family.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据